Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05146739
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:59.098189+00:00
Published At
2025-11-12T00:00:00+00:00
Record Updated At
2025-11-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia Post Cytotoxic Therapy", "Myelodysplastic Syndrome Post Cytotoxic Therapy", "Myeloid Leukemia Associated With Down Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Mixed Phenotype Acute Leukemia", "Refractory Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-11-12"
protocolSection.identificationModule.nctId
"NCT05146739"
protocolSection.identificationModule.officialTitle
"A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Myeloid Leukemia Post Cytotoxic Therapy (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome Post Cytotoxic Therapy (protocolSection.conditionsModule.conditions)
  • Myeloid Leukemia Associated With Down Syndrome (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Mixed Phenotype Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Refractory Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Mixed Phenotype Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.